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Abstract
Background: Cerebrospinal fluid (CSF) amyloid-beta (Aβ) peptides are predictive biomarkers for Alzheimer’s disease
and are proposed as pharmacodynamic markers for amyloid-lowering therapies. However, frequent sampling results
in fluctuating CSF Aβ levels that have a tendency to increase compared with baseline. The impact of sampling
frequency, volume, catheterization procedure, and ibuprofen pretreatment on CSF Aβ levels using continuous
sampling over 36 h was assessed.
Methods: In this open-label biomarker study, healthy participants (n = 18; either sex, age 55 − 85 years) were
randomized into one of three cohorts (n = 6/cohort; high-frequency sampling). In all cohorts except cohort 2
(sampling started 6 h post catheterization), sampling through lumbar catheterization started immediately post
catheterization. Cohort 3 received ibuprofen (800 mg) before catheterization. Following interim data review, an
additional cohort 4 (n = 6) with an optimized sampling scheme (low-frequency and lower volume) was included.
CSF Aβ1–37, Aβ1–38, Aβ1–40, and Aβ1–42 levels were analyzed.
Results: Increases and fluctuations in mean CSF Aβ levels occurred in cohorts 1–3 at times of high-frequency
sampling. Some outliers were observed (cohorts 2 and 3) with an extreme pronunciation of this effect. Cohort 4
demonstrated minimal fluctuation of CSF Aβ both on a group and an individual level. Intersubject variability in CSF
Aβ profiles over time was observed in all cohorts.
Conclusions: CSF Aβ level fluctuation upon catheterization primarily depends on the sampling frequency and
volume, but not on the catheterization procedure or inflammatory reaction. An optimized low-frequency sampling
protocol minimizes or eliminates fluctuation of CSF Aβ levels, which will improve the capability of accurately
measuring the pharmacodynamic read-out for amyloid-lowering therapies.
Trial registration: ClinicalTrials.gov NCT01436188. Registered 15 September 2011.
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Background
Alzheimer’s disease (AD) neuropathology is characterized
by deposition in the brain of amyloid plaques, consisting
mainly of amyloid-beta (Aβ) peptides, and neurofibrillary
tangles, composed of hyperphosphorylated tau protein.
Levels of cerebrospinal fluid (CSF) biomarkers Aβ and tau
closely reflect the central pathogenic processes in AD and
have proven their utility in evaluating disease risk or prog-
nosis, guiding clinical diagnosis and monitoring thera-
peutic interventions [1, 2].
Aβ peptides are proteolytic cleavage products of amyl-
oid precursor protein, formed by β- and γ-secretase ac-
tivity. Aβ species predominantly include peptides of 1–
40 amino acids (Aβ1–40) and 1–42 amino acids (Aβ1–42).
Several studies report pronounced increases in CSF Aβ
levels relative to baseline upon repeated CSF sampling
with spinal catheters [3–9]. Additionally, methodological
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challenges in measuring Aβ in CSF are well described,
but influencing factors are only partly understood [10–
13].
Considering these challenges, there is a clear need to
optimize and standardize the technique of continuous
CSF sampling and measurement of CSF Aβ for applica-
tion in clinical trials for Aβ-lowering compounds. We
performed a study utilizing continuous CSF sampling
with indwelling catheters over 36 h in healthy older
participants to evaluate the effects on CSF Aβ levels
when applying various sampling protocols. We investi-
gated the impact of sampling frequency, volume,
catheterization procedure, and pretreatment with an
anti-inflammatory agent (ibuprofen) on changes in CSF
Aβ levels over time. We also monitored the impact of
different sampling schemes and CSF volume on the
safety and tolerability of procedures.
Methods
Study population
Healthy men or women (n = 24; age 55–85 years, body
mass index (BMI) 18–35 kg/m2) with Mini-Mental State
Examination (MMSE) scores ≥27 were enrolled. None of
these participants had any significant history of or clinic-
ally significant current medical illness at screening or ad-
mission, and neither did they have any sign of
intracranial pressure as confirmed by fundoscopy.
Participants were excluded if they received the follow-
ing drugs: aspirin (even low dose) within 5 days, low
molecular weight heparin within 12 h, or anticoagulant
treatment (besides the heparin already described) within
1 week before spinal catheterization (Additional file 1:
Inclusion and exclusion criteria).
The study was conducted in accordance with the
ethical principles that have their origin in the Declar-
ation of Helsinki and that are consistent with current
International Conference on Harmonization (ICH)
guidelines on good clinical practices (GCP) and ap-
plicable regulatory requirements, and in compliance
with the study protocol. The study protocol was
reviewed and approved by the Institutional Review
Board (Commissie voor Medische Ethiek, ZNA, Antwerp,
Belgium). Written informed consent was obtained for par-
ticipation and a separate consent for pharmacogenomic
(DNA) sampling.
Study design
This open-label, single-center (Belgium), biomarker study
(ClinicalTrials.gov NCT01436188) without investigational
medicinal product, conducted between September 2011
and June 2013, consisted of a screening period (between
21 and 2 days before catheter insertion), an in-patient CSF
collection period (1–3 days), and a follow-up period (~7–
14 days after removal of the catheter). For each partici-
pant, the maximal study duration did not exceed 6 weeks
(Fig. 1).
Initially participants (n = 18) were randomized into
one of three cohorts (n = 6/cohort): cohort 1, high-
frequency CSF sampling scheme with immediate sam-
pling post catheterization; cohort 2, high-frequency CSF
sampling scheme with delayed sampling, starting 6 h
post catheterization; and cohort 3, high-frequency CSF
Fig. 1 Study design. Arrows indicate time points of CSF sampling post spinal catheter placement. Cohort 1 and Cohort 3: 0, 0.5, 1, 1.5, 2, 2.5, 3,
3.5, 4, 6, 8, 10, 12, 16, 20, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 30, 32, 34, and 36 h. Cohort 2: 0, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 12, 16, 20, 24, 24.5,
25, 25.5, 26, 26.5, 27, 27.5, 28, 30, 32, 34, and 36 h. Cohort 4: 0, 2, 4, 8, 24, 28, and 36 h. Per time point, 6 ml of CSF was collected for cohorts 1–3
and 4 ml was collected for cohort 4. LP lumbar puncture
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sampling scheme with immediate sampling and prelum-
bar puncture treatment with ibuprofen on day 1 (single
dose, 800 mg 2 h before catheterization). CSF was sam-
pled at the following time points post spinal catheter
placement for cohorts 1 and 3: 0, 0.5, 1, 1.5, 2, 2.5, 3,
3.5, 4, 6, 8, 10, 12, 16, 20, 24, 24.5, 25, 25.5, 26, 26.5, 27,
27.5, 28, 30, 32, 34, and 36 h. For cohort 2, the sampling
time points were as follows: 0, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5,
10, 12, 16, 20, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28,
30, 32, 34, and 36 h.
Following an interim review of the data from cohorts
1–3, six healthy older participants were allocated to an
additional cohort: cohort 4, low-frequency CSF sampling
scheme with immediate sampling. CSF was sampled at
the following time points post spinal catheter placement
for cohort 4: 0, 2, 4, 8, 24, 28, and 36 h (Fig. 1).
CSF sampling
CSF samples (6 ml for cohorts 1–3 and 4 ml for cohort
4, per time point) were collected over 36 h using a lum-
bar spinal indwelling CSF catheter. On day 1, all partici-
pants received a lumbar indwelling CSF catheter
(interspace of L3 and L4 or L4 and L5 of the lumbar
spine) between 6:00 and 9:00 a.m. The introducer needle
(Tuohy needle) with stylet in place was inserted at the
superior aspect of the inferior spinous process in the
midline and approximately 15° cephalad. The stylet was
removed and the peridural space was entered using a
loss of resistance technique. A Spinocath Catheter (22
Gauge; BBraun Melsungen AG, Germany) with a spinal
needle inside was introduced through the Tuohy needle to
perforate the dura mater (“dural pop”). The spinal needle
was withdrawn while moving up the spinal catheter into
the subarachnoid space for 10–15 cm (distance tip to
skin). The Tuohy needle was subsequently removed. To
reduce the risk of CSF leakage, participants were prefera-
bly placed on a bed, resting in a supine position during
sampling and for up to 12–24 h after removal of the cath-
eter. No specific cognitive activity was mandated, but
most participants were reading or listening to music.
CSF samples were collected with a syringe (BD Plasti-
pack 2 and 5 ml) under sterile conditions from the mo-
ment of catheter placement (0 h or baseline sample)
through the 36-h assessment period. Samples were col-
lected in 10 ml (catalog number 62.610.018)/12 ml (cata-
logue number 60.541.004) Sarstedt Liquor tubes, which
were immediately placed on melting ice and gently
inverted for adequate mixing. The collected CSF volume
was aliquoted by immediate transfer of 500 μl samples
to multiple storage tubes (Micronic 1.4 ml noncoded U-
bottom tubes in Comorack-96 (catalogue number
MP22502) with caps from FluidX (Split TPE Capcluster
Blue, catalogue number 65-53028)) and stored at −70 °C.
All sampling and processing materials used were ana-
lyzed for their Aβ adsorption capacity and were found
acceptable (<20 %) for avoiding any major influence on
the Aβ read-outs (unpublished data).
Analysis of CSF Aβ levels
A qualified, specific, and sensitive prototype multiplex im-
munoassay developed by Janssen Research & Development
and based on Meso Scale Discovery (MSD) electrochemilu-
minescence detection technology was utilized for simultan-
eous detection of four CSF Aβ species (Aβ1–37, Aβ1–38,
Aβ1–40, and Aβ1–42) [14, 15]. Purified monoclonal anti-
bodies specific for Aβx-37 (JRD/Aβ37/3), Aβx-38 (J&JPRD/
Aβ38/5), Aβx-40 (JRF/cAβ40/28), and Aβx-42 (JRF/cAβ42/
26) were coated on MSD 4-plex 96-well plates as capture
antibodies. JRF/AβN/25, which displays specificity for Aβ
isoforms with intact N-terminus (i.e., full-length Aβ), was
utilized as the detection antibody [16]. The CSF Aβ1–37,
Aβ1–38, Aβ1–40, and Aβ1–42 concentrations were deter-
mined using a standard curve with a four-parameter logistic
model with 1/Y2 weighting function.
One operator performed all of the experimental ana-
lyses for participants in cohorts 1–3, in a random fash-
ion over 3 consecutive days. The experimental analysis
for cohort 4 was performed by one operator on the same
day. All samples from each participant were analyzed in
duplicate on the same plate. Only mean values with a
replicate well coefficient of variation (CV) ≤20 % were
accepted.
Analysis of baseline CSF Aβ1–42, T-tau, and phosphorylated
tau181P levels
Baseline Aβ1–42, P-tau181P, and total tau (T-tau) concen-
trations (i.e., directly after catheter insertion) were mea-
sured utilizing INNO-BIA AlzBio3 kit reagents and the
Luminex analytical platform [17]. Diagnostic threshold
CSF concentrations for AD versus normal controls for
Aβ1–42 were applied to the current sample set to judge
the likelihood of having cerebral amyloid plaque depos-
ition [18].
Apolipoprotein E (APOE) epsilon 4 carrier status
Blood samples (10 ml) were collected in tubes contain-
ing potassium/sodium EDTA. DNA was isolated using
Puregene chemistry and automated extraction using an
Autopure LS. The aliquots of DNA samples from all
participants were genotyped in a multiplex reaction
using PCR/ligation detection reaction [19].
Safety assessments
Adverse events (AEs) were monitored. Laboratory tests,
examination of vital signs, resting 12-lead ECGs, phys-
ical and neurological examinations, and fundoscopy
were performed.
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Sample size
Based on CSF determinations of Aβ1–42, Aβ1–40, and
Aβ1–38 with a similar enzyme-linked immunosorbent
assay (ELISA) method (Janssen, unpublished data), the
CV of percentage change from baseline was estimated to
be ~13 %. A sample size of five completers per group
was expected to produce two-sided 95 % confidence in-
tervals with 16 % precision compared with natural fluc-
tuation of around 15 % in the reference study
(ClinicalTrials.gov NCT01556217) and was considered
reasonable for precise estimation of mean.
Results
Demographics, baseline characteristics, and AD biomarker
pattern
Twenty-four participants were enrolled, most were men
with mean age of 64 years. The average measures for
age, weight, height, BMI, and MMSE score at screening
were comparable among cohorts (p = 0.42, 0.16, 0.56,
0.66, and 0.45, respectively, F test) (Table 1). AD bio-
markers were analyzed. Two participants had Aβ1–42
below the threshold concentration (≤249 pg/ml) [18],
suggested to be pathologic, but none had elevated T-tau
or P-tau181P values (Additional file 2: Figure S1). Hence,
no participant had a typical AD biomarker pattern. All
participants completed the study.
CSF Aβ levels
Cohort 1: high-frequency CSF sampling scheme with imme-
diate sampling
Mean CSF Aβ1–40 levels fluctuated with a tendency for
increasing levels relative to baseline over the sampling
period (Fig. 2). CSF Aβ levels were particularly increased
during periods of frequent sampling (sampling every
30 min: 0–4 h and 24–28 h). After the 12-h time point,
two participants showed increases in CSF Aβ1–40 levels
of >20 % at several time points compared with baseline.
Other participants had a rather stable pattern of CSF Aβ
over the 36 h (Fig. 3a).
Cohort 2: high-frequency CSF sampling scheme with de-
layed sampling
In contrast to cohort 1, mean CSF Aβ1–40 levels at base-
line and 6 h post catheterization were similar in cohort
2 (Fig. 2). CSF Aβ levels increased in periods of frequent
sampling (sampling every 30 min: 6–10 h and 24–28 h).
Notably in cohort 2, unlike cohort 1, CSF Aβ levels
remained elevated after the first period of frequent
Table 1 Demographics and baseline characteristics of study participants by cohort (all randomized participants)
Cohort 1 Cohort 2 Cohort 3 Cohort 4 Total
(n = 6) (n = 6) (n = 6) (n = 6) (N = 24)
Age (years) 62 (4.3) 64 (6.4) 66 (1.7) 63 (3.3) 64 (4.3)
Sex (men), n (%) 6 (100.0) 5 (83.3) 6 (100.0) 5 (83.3) 22 (91.7)
Race, n (%)
White 6 (100.0) 6 (100.0) 5 (83.3) 6 (100.0) 23 (95.8)
Black or African American 0 0 1 (16.7) 0 1 (4.2)
Ethnicity, n (%)
Not Hispanic or Latino 6 (100.0) 6 (100.0) 6 (100.0) 6 (100.0) 24 (100.0)
Weight (kg) 83 (10.8) 72 (8.3) 77 (5.6) 79 (10.6) 78 (9.6)
Height (cm) 176 (7.8) 170 (9.5) 171 (9.2) 173 (7.6) 172 (8.4)
BMI (kg/m2) 27.1 (3.8) 25 (2.3) 26.6 (2.7) 26.6 (3.5) 26.3 (3.0)
Total MMSE at screening 29.2 (0.8) 29.0 (1.3) 29.7 (0.5) 29.7 (0.8) 29.4 (0.9)
Aβ1-42 (pg/ml) 393.2 (26.4) 380.6 (44.1) 326.1 (75.4) 319.2 (97.6) 354.8 (70.6)
T-tau (pg/ml) 74.5 (20.0) 62.7 (28.9) 46.7 (20.6) 50.7 (21.9) 58.6 (24.3)
P-tau181P (pg/ml) 30.7 (8.2) 22.2 (4.9) 20.4 (6.9) 24.9 (13.0) 24.6 (9.1)
APOE ε4 carrier
Yes 1 (16.7) 1 (16.7) 0 2 (33.3) 4 (16.7)
No 4 (66.7) 3 (50.0) 5 (83.3) 4 (66.7) 16 (66.7)
Unknown 1 (16.7) 2 (33.3) 1 (16.7) 0 4 (16.7)
Data shown as mean (standard deviation), unless otherwise specified
Cohort 1: immediate sampling, high frequency; cohort 2: delayed sampling, high frequency, procedure effect; cohort 3: ibuprofen, high frequency, inflammation
effect; cohort 4: immediate sampling, low frequency. APOE, apolipoprotein E gene; BMI, body mass index; MMSE, mini–mental state examination; Aβ, amyloid beta;
P-tau, phosphorylated tau; T-tau, total tau
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sampling. The elevation of mean Aβ levels was not limited
to the second period of frequent sampling (24–28 h), but
started before this period and extended beyond it. Fluctu-
ation of mean CSF Aβ1–40 over 36 h was higher in cohort
2 than in cohort 1. Increases in CSF Aβ over 36 h were
observed for all participants in cohort 2. After the 10-h
time point, one participant showed increased CSF Aβ1–40
levels of >60 % at many subsequent time points (Fig. 3b).
Cohort 3: high-frequency CSF sampling scheme with
immediate sampling and ibuprofen pretreatment
Mean CSF Aβ1–40 levels in this cohort showed more
fluctuation over 36 h than that observed for cohort 1
(Fig. 2). Similarly to cohorts 1 and 2, CSF Aβ levels in-
creased during periods of frequent sampling. Similar to
cohort 2, the CSF Aβ levels remained elevated after the
first period of frequent sampling. During the first period
of frequent sampling (0–4 h), all participants, except one
who showed the earliest increases in CSF Aβ levels, had
increased levels between 3 and 4 h. One participant
showed an increase in CSF Aβ1–40 levels >60 % (after
12 h) and >100 % (after 25 h) (Fig. 3c).
Several studies support γ-secretase modulator activ-
ity of ibuprofen [20, 21]. Mean baseline CSF Aβ1–42
levels were not significantly reduced in the ibuprofen-
treated cohort versus the other cohorts (Additional
file 2: Figure S1; p = 0.26, F test), suggesting that
800 mg ibuprofen did not lower baseline CSF Aβ1–42
levels.
Cohort 4: low-frequency CSF sampling scheme with
immediate sampling
Mean CSF Aβ1–40 levels over 36 h were more stable in
this cohort versus the high-frequency sampling schemes
(Fig. 2). Only one participant showed a pronounced in-
crease in the CSF Aβ1–40 levels, observed after the 28-h
time point (Fig. 3d).
For all cohorts, Aβ1–37, Aβ1–38, and Aβ1–42 were mea-
sured in addition to Aβ1–40 and similar profiles were
noted for mean change in Aβ levels versus baseline (data
not shown). The Aβ ratios showed lower intrasubject
variability than that observed for individual peptides
over time, suggesting that the effect of different sam-
pling schemes on CSF Aβ levels was similar for Aβ1–37,
Aβ1–38, Aβ1–40, and Aβ1–42.
Possible sources of intersubject variability
Intersubject variability was noted in all cohorts relat-
ing to increase in CSF Aβ levels over time. No correl-
ation was observed between increases in CSF Aβ
levels and sex, age, APOE ε4 status, MMSE score,
CSF sampling or sample processing issues, or baseline
levels of Aβ1–42, P-tau181P, and T-tau (Additional file 3:
Table S1).
A trend for a higher incidence of headache (10/15
(66.7 %)) was observed in participants with an Aβ in-
crease of >25 % versus baseline compared with partici-
pants with an Aβ increase <25 % (2/8 (25 %)) (Fisher’s
exact test: p = 0.089).
Fig. 2 Mean % change from baseline of CSF Aβ1–40 for all cohorts. Standard deviation is not shown for clarity of representation. Individual profiles
can be found in Fig. 3. Cohort 1: immediate sampling, high frequency; cohort 2: delayed sampling, high frequency, procedure effect; cohort 3:
ibuprofen, high frequency, inflammation effect; cohort 4: immediate sampling, low frequency. Aβ amyloid beta
Van Broeck et al. Alzheimer's Research & Therapy  (2016) 8:21 Page 5 of 9
Safety and tolerability of CSF sampling procedures
Nineteen (79.2 %) participants experienced at least
one AE, which was mild or moderate in severity, and
the majority of events were resolved at follow-up. In-
cidence of AEs was not significantly different across
cohorts (p = 0.11, Fisher’s exact test). Headache (n = 12
(50.0 %)), back pain (n = 7 (29.2 %)), and catheter-site pain
(n = 3 (12.5 %)) were most frequently reported, and were
possibly related to the sampling procedure (Table 2). There
was only one occurrence (4.2 %) of postdural puncture
headache. No clinically relevant changes in vital signs,
ECG, or laboratory measurements were noted. There were
no signs of inflammation as indicated by clinical laboratory
measurements.
Discussion
CSF Aβ concentrations were shown to be stable over
months to years in longitudinally collected samples with
isolated lumbar punctures [22, 23]. However, the intra-
subject CSF Aβ1–40 and Aβ1–42 levels varied largely and
tended to rise over 36 h after hourly sampling via an
intrathecal catheter in healthy participants [5]. Consist-
ent with other studies, an increase in CSF Aβ levels fol-
lowing serial samplings was noted in our study [3, 4, 6,
7, 9]. Factors such as frequency of sampling and sample
volume [4], diurnal effects [5, 7, 8], catheter interaction
with CSF Aβ at the first sampling time points, and activ-
ity [5, 7] were suggested to be related to this observed
increase. However, further studies to delineate the exact
mechanisms are needed.
We evaluated the effect of different CSF sampling proto-
cols on CSF Aβ levels in an older population to reflect the
age range of the target population for AD. Earlier studies
mainly describe CSF Aβ changes for younger healthy par-
ticipants. A study comparing data from older healthy con-
trols and AD patients showed that the variation in CSF
measures of Aβ1–40, Aβ1–42, T-tau, and P-tau181P was
comparable [8]. On the other hand, hour-to-hour fluctua-
tions in CSF biomarkers were lower in older healthy con-
trols and AD patients than in young participants [5],
Fig. 3 Individual CSF Aβ1–40 profiles for all participants per cohort. a Cohort 1: immediate sampling, high frequency. b Cohort 2: delayed
sampling, high frequency, procedure effect. c Cohort 3: ibuprofen, high frequency, inflammation effect. d Cohort 4: immediate sampling, low
frequency. APOE ε4 carriers are indicated in red with a square or diamond symbol. Cohort 1: only five participants are shown; one participant
(participant 6) did not have a baseline sample available. Aβ amyloid beta (Color figure online)
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underscoring the importance of investigating these
changes in the target population.
Our results corroborated earlier findings indicating a
higher increase in CSF Aβ levels with protocols using
high sampling frequency compared with protocols using
low sampling frequency [4]. The increases in Aβ levels
relative to baseline were more prominent during high-
frequency sampling (every 30 min) in cohorts 1–3, while
the Aβ levels were relatively stable in samples drawn
every 4 h. Although the first period of frequent sampling
occurs at a different time during the day for cohort 2
compared with cohorts 1 and 3, clear mean increases in
CSF Aβ levels were seen in high-frequency sampling pe-
riods for all cohorts. Together with the fact that the
average Aβ levels did not return to baseline after 24 h,
this suggests that the observed increase in our study
could not be explained solely by a diurnal effect.
Interestingly, Aβ levels at baseline and 6 h post
catheterization were similar in cohort 2, suggesting that
the increase in Aβ levels was not related to the catheter
insertion procedure. Furthermore, precatheterization ad-
ministration of ibuprofen did not impact the increased
CSF Aβ levels. These findings indicate that the increase
in CSF Aβ levels was not related to the procedure of
catheterization itself, including any kind of induced in-
flammatory reaction. Together, these data support the
hypothesis that the intense sampling frequency applied
in these cohorts probably impacted CSF Aβ levels.
After the interim review of the data from cohorts 1–3, it
was hypothesized that a lower CSF sampling frequency over
36 h may result in more stable Aβ profiles. An additional
cohort (cohort 4) of healthy older participants was included
to assess an alternative low-frequency CSF sampling
scheme. This sampling scheme, with a lower total volume
of CSF sampled, resulted in more stable mean CSF Aβ
levels over 36 h versus high-frequency sampling schemes.
These data support the hypothesis that the increase in CSF
Aβ levels compared with baseline level is probably related
to either CSF sampling frequency or volume, or both. The
underlying mechanism of the rise in CSF Aβ concentrations
after frequent CSF sampling is unknown. Various stimuli,
including stress and sleep deprivation, could increase brain
Aβ levels, possibly through modulation of neuronal activity
[24]. Moreover, frequent sampling in the lumbar region
might alter a possible rostral–caudal Aβ gradient from ven-
tricular to lumbar CSF by induction of redistribution of
Table 2 Incidence of adverse events occurring during study (starting after catheter insertion)
Cohort 1 Cohort 2 Cohort 3 Cohort 4 Total
(n = 6) (n = 6) (n = 6) (n = 6) (N = 24)
Participants with one or more adverse event 6 (100.0) 6 (100.0) 3 (50.0) 4 (66.7) 19 (79.2)
Headache 3 (50.0) 5 (83.3) 2 (33.3) 2 (33.3) 12 (50.0)
Back pain 1 (16.7) 2 (33.3) 1 (16.7) 3 (50.0) 7 (29.2)
Catheter site pain 2 (33.3) 0 1 (16.7) 0 3 (12.5)
Dizziness postural 0 1 (16.7) 0 1 (16.7) 2 (8.3)
Hypoesthesia 1 (16.7) 0 1 (16.7) 0 2 (8.3)
Pain in extremity 1 (16.7) 0 1 (16.7) 0 2 (8.3)
Nausea 0 1 (16.7) 1 (16.7) 0 2 (8.3)
Musculoskeletal stiffness 0 1 (16.7) 0 0 1 (4.2)
Neck pain 0 0 1 (16.7) 0 1 (4.2)
Gastroesophageal reflux disease 0 0 1 (16.7) 0 1 (4.2)
Regurgitation 0 0 0 1 (16.7) 1 (4.2)
Toothache 0 0 0 1 (16.7) 1 (4.2)
Dermatophytosis 0 0 1 (16.7) 0 1 (4.2)
Sinusitis 0 0 0 1 (16.7) 1 (4.2)
Post lumbar puncture syndrome 0 1 (16.7) 0 0 1 (4.2)
Pruritus 1 (16.7) 0 0 0 1 (4.2)
Flushing 0 1 (16.7) 0 0 1 (4.2)
Data shown as n (%). Cohort 1: immediate sampling, high frequency; cohort 2: delayed sampling, high frequency, procedure effect; cohort 3: ibuprofen, high
frequency, inflammation effect; cohort 4: immediate sampling, low frequency
The laboratory parameters (clinical chemistry, hematology, urinalysis) were evaluated at screening, on days –1 and 2, and during follow-up (days 7–14 after re-
moval of the spinal catheter). The vital signs and resting 12-lead ECGs were evaluated at screening, on days –1, 1, and 2, and during follow-up. The participants
were physically and neurologically examined at screening, on days 1 and 3, and in follow-up. Fundoscopy was performed at screening to exclude
intracranial pressure
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CSF to the lumbar region [4]. The disease state may also in-
fluence the CSF Aβ levels and thus studies in AD patients
are warranted [8].
One out of six participants in cohort 4 demonstrated a
rise in CSF Aβ levels after 24 h post catheterization. This
increase does not seem to be related to gender, age, race,
APOE status, MMSE score, or adverse events (Additional
file 3: Table S1). As such, a possible explanation for this
finding is currently unclear, but might for example include
a difference in activity level of this participant. Only one
participant in cohort 4 had an Aβ1–42 concentration
slightly below the threshold concentration, excluding the
possibility that greater amyloid deposition in cohort 4
would be responsible for the observed stability of CSF Aβ
concentrations over time in this cohort [25].
Conclusions
CSF Aβ levels were substantially affected by CSF sam-
pling frequency and/or sampling volume. An optimized
sampling protocol with lower CSF sampling frequency
and volume resulted in more stable Aβ profiles. In future
clinical studies with Aβ-targeting experimental drugs,
this protocol would lead to a better estimation of drug
effects on Aβ levels after continuous CSF sampling and
thus lower the required sample size. The described pro-
tocols for continuous CSF sampling were well tolerated
with no clinically important safety concerns in healthy
older participants. These results substantiate the poten-
tial of CSF Aβ as a pharmacodynamic biomarker using
frequent CSF sampling to assess evidence of target en-
gagement and pharmacological activity of Aβ-targeting
compounds.
Statistical analysis
JB was the project statistician (Janssen Research &
Development, LLC, Raritan, NJ, USA).
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